Category - Markets

Roth Capital Partners raised its price target for Recro Pharma (NASDAQ:REPH) to $10 from $7.50 but maintained a “neutral” rating, pending greater understanding of the company’s contract development and manufacturing...

BTIG upgraded iRhythm Technologies (NASDAQ:IRTC) to “buy” with an $80 price target, citing a drastic pullback in the stock that “opens a window of opportunity.” The stock closed at $69.34 on April 2. “For a long time...

BTIG upgraded AtriCure (NASDAQ:ATRC) to “buy” from “neutral” with a price target of $35 based on the shares having recently slid. The stock closed at $27.37 on April 1. At a current 3.8 times enterprise value/next 12...

Ladenburg Thalmann raised its price target for TG Therapeutics (NASDAQ:TGTX) to $39 from $27 after the company presented positive interim data from a Phase 2b pivotal trial in relapsed/refractory marginal zone lymphoma...

Canaccord Genuity initiated coverage of ShockWave Medical (NASDAQ:SWAV) with a “buy” rating and $39 price target. The stock closed at $33.47 on March 29. Analyst Jason Mills writes that ShockWave’s technology –...

Maxim Group downgraded Proteon Therapeutics (NASDAQ:PRTO) to “hold” from “buy” and withdrew its previous $5 price target after the company’s second Phase 3 study of vonapanitase failed to reach statistical significance...

EyePoint Pharmaceuticals (NASDAQ:EYPT) priced a public offering of 10,526,500 of its common shares at a price of $1.90 each to raise about $20-million. EyePoint also granted underwriters a 30-day option to purchase up...

SVB Leerink launched coverage of Fate Therapeutics (NASDAQ:FATE) with an “outperform” rating and $20 price target. The stock closed at $16.71 on March 27. Analyst Daina Graybosch writes that Fate is at the forefront of...

SVB Leerink initiated coverage of Affimed NV (NASDAQ:AFMD) with an “outperform” rating and $8 price target. The stock closed at $4.17 on March 27. “Our positive view is fuelled by the potential of the company’s novel...

Maxim Group raised its price target for Atossa Genetics (NASDAQ:ATOS) to $9 from $5 after the Institutional Review Board approved the use of oral endoxifen as a post-mastectomy treatment in pre-menopausal, estrogen...